Edesa Biotech Current Ratio 2013-2021 | EDSA

Edesa Biotech current ratio from 2013 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Edesa Biotech Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.01B $0.00B 14.58
2021-03-31 $0.02B $0.01B 4.64
2020-12-31 $0.01B $0.00B 8.46
2020-09-30 $0.01B $0.00B 5.30
2020-06-30 $0.01B $0.00B 6.33
2020-03-31 $0.01B $0.00B 12.83
2019-12-31 $0.01B $0.00B 6.86
2019-09-30 $0.01B $0.00B 12.23
2019-06-30 $0.01B $0.00B 7.02
2019-03-31 $0.01B $0.00B 9.23
2018-12-31 $0.00B $0.00B 18.45
2018-09-30 $0.01B $0.00B 21.60
2018-06-30 $0.01B $0.00B 28.06
2018-03-31 $0.00B $0.00B 7.24
2017-12-31 $0.01B $0.00B 9.85
2017-09-30 $0.01B $0.00B 21.06
2017-06-30 $0.01B $0.00B 19.09
2017-03-31 $0.01B $0.00B 21.57
2016-12-31 $0.01B $0.00B 17.59
2016-09-30 $0.01B $0.00B 19.40
2016-06-30 $0.01B $0.00B 9.21
2016-03-31 $0.01B $0.00B 14.15
2015-12-31 $0.01B $0.00B 13.39
2015-09-30 $0.01B $0.00B 4.15
2015-06-30 $0.01B $0.00B 6.02
2015-03-31 $0.01B $0.00B 3.94
2014-12-31 $0.01B $0.00B 3.29
2014-09-30 $0.01B $0.00B 21.52
2014-08-31 $0.01B $0.00B 9.90
2014-06-30 $0.01B $0.00B 9.90
2014-05-31 $0.00B 0.00
2014-03-31 $0.02B $0.00B 9.09
2013-12-31 $0.00B 0.00
2013-09-30 $0.01B $0.00B 2.10
2013-08-31 $0.00B 0.00
2013-06-30 $0.00B $0.00B 5.55
2013-03-31 $0.00B $0.00B 2.18
2012-12-31 $0.00B $0.00B 3.02
2012-09-30 $0.00B $0.00B 1.86
2012-06-30 $0.00B $0.00B 5.64
2012-03-31 $0.00B $0.00B 9.61
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.102B $0.000B
Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86